FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)



Therapeutic canine immunoglobulins and methods of using same
02/26/15 - - A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen. Canine derived antibodies...

Protein belonging to the tnf superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereof
02/26/15 - 20150056184 - A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting...

Immunoglobulin constant region fc receptor binding agents
02/26/15 - 20150056185 - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are...

Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
02/26/15 - 20150056186 - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2...

Humanized antibodies that recognize alpha-synuclein
02/26/15 - 20150056187 - The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease....

Jcv neutralizing antibodies
02/26/15 - 20150056188 - In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some...

Cdr-modified anti-siglec-15 antibody
02/26/15 - 20150056189 - Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like....

Diagnostic methods and compositions for treatment of cancer
02/26/15 - 20150056190 - The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods....

Igf1 biomarker for igf1r inhibitor therapy
02/26/15 - 20150056191 - The present invention provides, inter alia, methods for treating tumors that are sensitive to an IGF1R inhibitor. The tumor are determined to be sensitive if the level of IGF1 mRNA expression in the tumor cells, relative to one or more reference genes, reaches a certain threshold level. Methods for evaluating...

Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
02/26/15 - 20150056192 - The invention provides for compositions for treating a cancer or an inflammatory disorder comprising a combination of agents in a pharmaceutically acceptable carrier, wherein said agents comprise: (i) a non-covalent DNA binding agent; and (ii) an anti-cancer or anti-inflammatory agent....

Egfr and ros1 kinase in cancer
02/26/15 - 20150056193 - The present disclosure provides methods of that include detecting in a biological sample from a patient having or suspected of having cancer the presence of a polypeptide having ROS1 kinase activity or a polynucleotide encoding the same and detecting in the biological sample the presence of a mutant EGFR polypeptide...

Modified green tea polyphenols and methods thereof for treating liver disease
02/26/15 - 20150056194 - Methods of treating liver disease in a subject, including administering to the subject an effective amount of one or more modified green tea polyphenols to reduce, decrease, limit or prevent one or more symptoms of liver disease relative to an untreated control subject are provided. In a preferred embodiment the...

Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy
02/26/15 - 20150056195 - The invention relates to the field of oncology and to chemotherapy resistance and relapse. Thus the invention provides compositions and methods for inhibiting tumorigenicity of senescent cancer cells induced by a chemotherapeutic agent. The invention also provides compositions and methods for inhibiting conversion of non-stem cancer cells (non-CSCs) into tumor...

Antibody purification by cation exchange chromatography
02/26/15 - 20150056196 - A method for purifying an antibody by cation exchange chromatography is described in which a high pH wash step is used to remove of contaminants prior to eluting the desired antibody using an elution buffer with increased conductivity....

Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
02/19/15 - - This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA...

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
02/19/15 - 20150050267 - The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described....

Prolonged inhibition of interleukin-6 mediated signaling
02/19/15 - - Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that...

Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
02/19/15 - 20150050269 - The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as...

Antibodies to bradykinin b1 receptor ligands
02/19/15 - 20150050270 - The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin...

Jcv neutralizing antibodies
02/19/15 - 20150050271 - In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some...

Method of dynamic spectroscopy under physiological conditions
02/19/15 - 20150050272 - The present invention relates to the field of dynamic spectroscopy and more precisely to a method involving dynamic molecules spectroscopy technology designed to determine transitional changes in molecules conformation and assemblies both in physiologic and pathologic conditions. The method comprises in vitro fingerprints of a sample taken under highly controlled...

Afucosylated anti-fgfr2iiib antibodies
02/19/15 - 20150050273 - The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided....

Methods and biomarkers for detection and treatment of mature t-cell leukemia
02/19/15 - 20150050274 - The present invention relates to methods and biomarkers for detection and characterization of mature T-cell neoplasias/leukemias (e.g., T-cell prolymphocytic leukemia, Sezary syndrome) in biological samples (e.g., tissue samples, blood samples, plasma samples, cell samples, serum samples)....

Purification of anti-c-met antibodies
02/19/15 - 20150050275 - Provided herein are methods of purifying anti-c-met antibodies, compositions and pharmaceutical formulations comprising purified anti-c-met antibodies, and methods of using the same....

High affinity antibodies that neutralize staphylococcus enterotoxin b
02/19/15 - 20150050276 - Provided herein are antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B....

Antibodies that specifically bind to the epha2 receptor
02/12/15 - 20150044197 - The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate....

Reduced-viscosity concentrated protein formulations
02/12/15 - 20150044198 - The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations....

Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
02/12/15 - 20150044199 - The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2....

Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
02/12/15 - 20150044200 - The present invention relates to the treatment or prevention of tinnitus. More precisely, the present invention relates to a compound modulating chloride co-transporter NKCC1 (chloride co-transporter modulator) for use in the treatment of tinnitus. In addition, the present invention concerns pharmaceutical compositions comprising such an NKCC1 chloride co-transporter modulator as...

Cyclon expression for the identification and control of cancer cells
02/12/15 - 20150044201 - The present disclosure concerns a method for the identification of the presence or absence of cancer cells in a biological sample, more particularly a method for the identification of the susceptibility or resistance to a treatment with CD20 agonists of cancer cells in a biological sample, the methods including determining...

Methods for reducing exacerbation rates of asthma using benralizumab
02/12/15 - 20150044202 - Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof....

Methods for increasing forced expiratory volume in asthmatics using benralizumab
02/12/15 - 20150044203 - Provided herein is are methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof....

Methods for improving asthma symptoms using benralizumab
02/12/15 - 20150044204 - Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof....

Compositions and method for treating compliment-associated conditions
02/12/15 - 20150044205 - The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive...

Immunoglobulin formulation and method of preparation thereof
02/12/15 - 20150044206 - A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of...

Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
02/05/15 - 20150037319 - The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step....

Treatment of macrophage-related disorders
02/05/15 - 20150037320 - The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in...

Methods and compositions for inhibiting cd32b expressing cells
02/05/15 - 20150037321 - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins....

Methods and compositions for inhibiting cd32b expressing cells
02/05/15 - 20150037322 - The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins....

Humanized axl antibodies
02/05/15 - 20150037323 - The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity....

Antibodies and methods of treating cancer
02/05/15 - 20150037324 - Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies....

Slit-robo signaling for diagnosis and treatment of kidney disease
02/05/15 - 20150037325 - Provided herein are methods for the treatment of chronic kidney disease and proteinuria and for the diagnosis of chronic kidney disease and monitoring the effects of treatment on the progression of chronic kidney disease and proteinuria based on unexpected roles for the SLIT-ROBO signaling pathway in the regulation of podocyte...

Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
02/05/15 - 20150037326 - The present invention is directed to a pharmaceutical composition including (eg for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components and as a cargo at least one nucleic acid (molecule) and at least one antigen associated with...

Mirna based treatment monitoring in multiple sclerosis
02/05/15 - 20150037327 - The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose...

Anti-cxcr4 antibodies and antibody-drug conjugates
02/05/15 - 20150037328 - The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates...

Method of reducing titers of antibodies specific for a therapeutic agent
02/05/15 - 20150037329 - The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which...

Histamine-releasing factor (hrf), hrf-receptor and methods of modulating inflammation
02/05/15 - 20150037330 - Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity,...

Il-31 monoclonal antibodies
02/05/15 - 20150037331 - The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by...

Treatment of metastic breast cancer
02/05/15 - 20150037332 - The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or...

Compositions including triciribine and one or more platinum compounds and methods of use thereof
01/29/15 - 20150030585 - This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation....

Compositions and methods for the therapy and diagnosis of cancer
01/29/15 - 20150030586 - Compositions and methods for the therapy and diagnosis of cancer are disclosed. For example, illustrative compositions comprise one or more cancer-associated antibodies, polypeptides, polynucleotides, antigen presenting cells, and the like. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly cancer....

Human papilloma virus as predictor of cancer prognosis
01/29/15 - 20150030587 - Methods of treating a head and neck cancer are disclosed....

Combination of kinase inhibitors and uses thereof
01/29/15 - 20150030588 - The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In...

Abeta antibody formulation
01/29/15 - 20150030589 - The present invention relates to a pharmaceutical formulation comprising about 50 mg/ml-200 mg/ml of an Abeta antibody, about 0.01%-0.1% poloxamer, about 5 mM-50 mM of a buffer, about 100 mM-300 mM of a stabilizer at a pH of about 4.5-7.0....

Treatment of severe multiple sclerosis
01/29/15 - 20150030590 - Methods of treating multiple sclerosis are disclosed....

High concentration antibody and protein formulations
01/29/15 - 20150030591 - Provided are salt-free antibody and other protein formulations that are substantially isosmotic and of low viscosity. Also provided are methods for the treatment of diseases using the disclosed formulations....

Optimized fc variants
01/29/15 - 20150030592 - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants....

Anti-vegf antibodies
01/22/15 - 20150023951 - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo....

Anti-addl monoclonal antibody and uses thereof
01/22/15 - 20150023952 - The present invention relates to antibodies that bind amyloid β-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to...

Method of treating cancer
01/22/15 - 20150023953 - Methods are provided for treating cancer in a patient in need thereof with a HER2 inhibitor, where such patients have certain polymorphisms in VEGFA, VEGFR or IGF1R....

Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
01/22/15 - 20150023954 - Methodologies and technologies for potentiating antibody-based cancer treatments by increasing complement-mediated cell cytotoxicity are disclosed. Further provided are methodologies and technologies for overcoming ineffective treatments correlated with and/or caused by sub-lytic levels of complement-activating monoclonal antibodies (“mAb”) against cancer antigens or cancer antigens with low tumor cell density. While detectable...

Treatment and diagnosis of melanoma
01/22/15 - 20150023955 - The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods....

Monoclonal antibodies that neutralize anthrax toxins
01/15/15 - 20150017153 - The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies....

Anti-nerve growth factor antibodies and methods of preparing and using the same
01/15/15 - 20150017154 - A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (NGF) and neutralise the ability of canine NGF to bind to the p75 or TrkA canine NGF receptor. The invention extends to nucleic...

Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
01/15/15 - 20150017155 - The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such...

Esx-mediated transcription modulators and related methods
01/15/15 - 20150017156 - The present invention relates to gene regulation. In particular, the present invention provides small compounds capable of modulating ESX-mediated transcription and related methods of therapeutic and research use. In addition, the present invention provides methods for treating conditions associated with aberrant EGFR expression with ESX-mediated transcription modulators (e.g., ESX-mediated transcription...

Methods for treating acne
01/15/15 - 20150017157 - The present disclosure relates to methods and materials for treating acne in a subject including, for example, moderate and/or severe acne, using anti-IL-1β binding molecules such as an anti-IL-1β antibody or binding fragment thereof....

Tetrahydrofolates in combination with egfr-inhibitors
01/15/15 - 20150017158 - The present invention relates a pharmaceutical composition comprising an EGFR inhibitor and methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate, for use in the treatment of cancer. The methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate enhances the anticancer efficacy of the EGFR inhibitor. The cancers that may be treated include breast cancer, gastric cancer, gastrointestinal cancer, gall...

Monocyte biomarkers for cancer detection
01/15/15 - 20150017159 - The disclosure relates to the field of biomarkers to diagnose a disease, more particularly to the field of biomarkers to diagnose cancer, and most particularly to colorectal cancer. Specifically, these biomarkers are expressed in monocytes of a subject, particularly circulating monocytes, as can be isolated from peripheral blood. The markers...

Combinations and uses thereof
01/15/15 - 20150017160 - The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib....

Humanized pai-1 antibodies and uses thereof
01/08/15 - 20150010536 - The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy...

Genetic variations associated with tumors
01/08/15 - 20150010537 - Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided....

Anti-cd25 antibodies and their uses
01/08/15 - 20150010538 - The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis....

Anti-cd25 antibodies and their uses
01/08/15 - 20150010539 - The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis....

Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
01/08/15 - 20150010540 - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate....

Macrocyclic compounds useful as inhibitors of histone deacetylases
01/08/15 - 20150010541 - The present invention provides a novel macrocyclic compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound....

Antibodies to toso
01/08/15 - 20150010542 - The present invention provides methods and compositions for modulating Toso activity and treating diseases and disorders in which Toso is implicated. Such methods and compositions include the use of one or more antibodies that bind to a Toso protein or to a ligand of a Toso protein....

Optimized fc variants
01/08/15 - 20150010543 - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants....

Compounds and methods for treating inflammatory diseases
01/08/15 - 20150010544 - A monoclonal secretory IgA antibody, which binds to and neutralizes human p40 (the p40 subunit of IL-12 and IL-23). The secretory antibody is useful in treating a variety of inflammatory conditions in humans....

Methods for treatment of breast cancer nonresponsive to trastuzumab
01/08/15 - 20150010545 - The present invention provides a method of treating breast cancer that is nonresponsive to treatment with trastuzumab, comprising administering to a subject in need of such treatment a therapeutically effective amount of compound N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or a pharmaceutically acceptable salt thereof....

Sequences directed against hepatocyte growth factor (hfg) and polypeptides comprising the same for the treatment of cancers and/or tumors
01/08/15 - 20150010546 - The present invention relates to biological materials against HGF and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic,...

Treatment of allergic diseases with recombinant antibodies
01/08/15 - 20150010547 - Recombinant antibodies (including binding fragments thereof) that bind IgE are described, along with compositions and methods of using the same in the treatment of subjects in need thereof, including subjects afflicted with atopic dermatitis, allergic rhinitis, allergic conjunctivitis, urticaria, gastro-intestinal inflammation, or oral-pharyngeal inflammation. In some embodiments, the antibody is...

Stabilized aqueous antibody compositions
01/08/15 - 20150010548 - The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine, wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range n=2-12....

Methods of treating amyotrophic lateral sclerosis
01/08/15 - 20150010549 - The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ALS, by administering these compounds or pharmaceutical compositions to subjects in need thereof....

Optimized fc variants
01/08/15 - 20150010550 - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants....

Compositions and methods of treating tumors
01/08/15 - 20150010551 - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is...

Compositions and methods for treating inflammation and fibrosis
01/08/15 - 20150010552 - The present invention features compositions featuring agents that bind to denatured collagen and methods of using such agents to treat or prevent fibrosis or inflammation in a subject....

Methods of treating inflammatory diseases using antibodies that bind both il-17a and il-17f
01/08/15 - 20150010553 - The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of...

Methods for treating interleukin-6 related diseases
01/08/15 - 20150010554 - A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R)....